Cell therapy weekly: Affini-T Therapeutics joins forces with ElevateBio to advance T-cell therapy programs for solid tumors
This week: New all-in-one AAV production system launched by Thermo Fisher Scientific, Affini-T Therapeutics joins forces with ElevateBio to advance T-cell therapy programs for solid tumors and Kriya acquires Redpin to expand its gene therapy portfolio to include neurology targets
The news highlights:
New all-in-one AAV production system launched by Thermo Fisher Scientific
Thermo Fisher Scientific (MA, USA) unveiled the Gibco CTS AAV-MAX Helper-Free AAV Production System, an all-in-one solution for the development of adeno-associated virus (AAV)-based gene therapies. It is designed to ease the transition from research to manufacturing and is the only product of its kind manufactured under cGMP conditions. It has a mammalian-based suspension system made up of a clonal HEK293 cell line and chemicals free of animal origin.
Amy Butler, president of biosciences at Thermo Fisher Scientific stated: “Building on 60 years of trusted Gibco solutions, the CTS AAV-MAX System is the latest addition to our fit-for-purpose line of scalable solutions for commercial manufacturing of cell and gene therapy applications. More efficient, cost-effective AAV production is an essential step to streamline gene therapy development, helping drive innovation to serve those who need it most – patients who can benefit from these potentially life-changing therapies.”
Affini-T Therapeutics joins forces with ElevateBio to advance T-cell therapy programs for solid tumors
ElevateBio, (MA, USA) and Affini-T Therapeutics (MA, USA) have announced a partnership to advance Affini-T’s engineered TCR T-cell therapies focused on Kirsten rat sarcoma viral oncogene homolog. In solid tumor cancers, Kirsten rat sarcoma viral oncogene homolog is one of the most prevalent oncogenic driver mutations. Affini-T will leverage ElevateBio Basecamp’s LentiPeak™ viral vector platform and cell therapy production capabilities to drive its oncogenetic driver programs into clinical development.
Kim Nguyen, Chief Technical Officer at Affini-T Therapeutics stated: “Affini-T is pioneering novel T cell therapy approaches to treat solid tumor cancers by striking at the core of tumor biology, which entails leveraging the most advanced tools and techniques in cell engineering. Deep expertise in autologous cellular therapies manufacturing and analytics combined with its scalable platform for suspension-based lentiviral production, make ElevateBio an ideal partner as we progress our oncogenic driver programs into the clinic and work to deliver transformative therapies to patients and their families.”
Kriya acquires Redpin to expand its gene therapy portfolio to include neurology targets
Kriya Therapeutics (CA, USA), has acquired Redpin Therapeutics (NY, USA), a biotechnology company focusing on the development of gene therapies for intractable diseases of the nervous system. Kyria is a fully integrated company developing a diverse pipeline of gene therapies with many targets. This acquisition will provide Kriya with its first gene therapy programs in the therapeutic area of neurology.
Shankar Ramaswamy, co-founder and CEO of Kriya Therapeutics stated: “Redpin’s innovative chemogenetics platform has the potential to transform the lives of patients suffering from intractable neurological conditions. We are looking forward to integrating Redpin’s platform and pipeline into Kriya’s gene therapy engine as we advance our mission to develop life-changing gene therapies that can address diseases affecting millions of patients around the world.”
You might also like: